Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Miyoshi Kasei Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 2 actions are being reviewed by 2 distinct examiners and are located in 2 distinct art units. This one-to-one ratio between actions, examiners, and art units indicates a diverse range of technical sub-specialties or varied filing strategies for a portfolio of this size.
The busiest examiner for the portfolio is BROWE, DAVID, who is responsible for 1 pending office action. Since each of the 2 pending actions is assigned to a different examiner, no single individual dominates the current prosecution landscape. This lack of concentration means that practitioners cannot rely on a single examiner's history to predict outcomes across the portfolio. Each application represents a unique interaction with a different part of the patent office's administrative structure.
Operating across 2 distinct art units within the Biotechnology & Pharmaceuticals field suggests that Miyoshi Kasei Inc. is pursuing protection for different technical aspects of its technology. The administrative complexity is higher than a centralized portfolio, as each of the 2 pending matters requires engagement with a different examiner and a different art unit. Success in this environment depends on managing two unique prosecution tracks simultaneously while addressing the specific technical requirements of each distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BROWE, DAVID | 1 | 26.7% | +28.0% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.6% | +62.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720733 | AQUEOUS DISPERSION AND COSMETIC | BROWE, DAVID | — |
| 17629606 | HYDROPHILIZED INORGANIC POWDER AND COSMETIC INCLUDING HYDROPHILIZED INORGANIC POWDER | HOERNER, PAUL ELLSWORTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720733 | AQUEOUS DISPERSION AND COSMETIC | BROWE, DAVID | — |
| 17629606 | HYDROPHILIZED INORGANIC POWDER AND COSMETIC INCLUDING HYDROPHILIZED INORGANIC POWDER | HOERNER, PAUL ELLSWORTH | — |
| Art Unit | Apps |
|---|---|
| 1617 | 1 |
| 1611 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18720733 | AQUEOUS DISPERSION AND COSMETIC | BROWE, DAVID | 1617 | §103§112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 17629606 | HYDROPHILIZED INORGANIC POWDER AND COSMETIC INCLUDING HYDROPHILIZED INORGANIC POWDER | HOERNER, PAUL ELLSWORTH | 1611 | §103§112 | Non-Final OA | — | Pending | Jan 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMiyoshi Kasei Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
David Browe has the most, with 1 of Miyoshi Kasei Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
